TGFB2 and central nervous system cancer: TGFB2 can be directly targeted using TGFB2-specific synthetic phosphorothioate antisense oligodeoxynucleotide (OT-101) [75], which reached completion in phase 2 clinical trials in gliomas and pancreatic cancer.